Uncertainty over Skyclarys decision as HSE team to meet

The Health Service Executive (HSE) has approved reimbursement for the drug Skyclarys, which is the first treatment for Friedreich's Ataxia, a rare, progressive neuromuscular condition affecting around 200 people in Ireland. This decision comes after a substantial increase in Biogen's financial offer to the HSE. The HSE Senior Management Team met and decided to approve reimbursement based on the new commercial offer.

Friedreich's Ataxia is a condition characterized by nerve damage, muscle weakness, and mobility loss. Minister for Health Jennifer Carroll MacNeill acknowledged the complex process involved in making such decisions and emphasized the importance of allowing science to be the decision-maker, rather than politics. HSE Chief Clinical Officer Dr Colm Henry recognized the distress caused by the wait for the outcome of negotiations with Biogen, but stressed that without these negotiations, the HSE would have significantly less financial resources to allocate within the health service.

Biogen expressed that this decision is a landmark moment for people living with Friedreich's Ataxia and is committed to working closely with the HSE to facilitate access to treatment as quickly as possible. The drug has been approved by the European Medicines Agency and the US Food and Drug Administration.

While the decision to reimburse Skyclarys has been widely welcomed, opposition parties criticized the lengthy process. Sinn Féin leader Mary Lou McDonald called for an end to delays, while the Social Democrats' Health spokesperson Pádraig Rice highlighted major flaws in the existing process.